Pancreatic Ductal Adenocarcinoma Treatment Pipeline Shows Strong Momentum as 80+ Pharma Companies in the Race | DelveInsight

DelveInsight's, "Pancreatic Ductal Adenocarcinoma Pipeline Insight, 2026" report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in Pancreatic Ductal Adenocarcinoma pipeline landscape. It covers the Pancreatic Ductal Adenocarcinoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Pancreatic Ductal Adenocarcinoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Pancreatic Ductal Adenocarcinoma Pipeline @ https://www.delveinsight.com/sample-request/pancreatic-ductal-adenocarcinoma-pipeline-insight [https://www.delveinsight.com/sample-request/pancreatic-ductal-adenocarcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Pancreatic Ductal Adenocarcinoma Pipeline Report

* On February 27, 2026- Arcus Biosciences, Inc . initiated a phase 3 study is to compare overall survival of quemliclustat, nab-paclitaxel and gemcitabine versus placebo, nab-paclitaxel and gemcitabine in all randomized patients.
* On February 27, 2026- Engeneic Pty Limited announced a study is to evaluate the safety and tolerability and overall survival (OS) of E-EDV-D682/GC in combination with gemcitabine and nab-paclitaxel versus gemcitabine and nab-paclitaxel alone in participants with metastatic pancreatic ductal adenocarcinoma (PDAC) who have progressed on therapy.
* On February 27, 2026- Ipsen announced a Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours
* On February 25, 2026- Blue Earth Diagnostics announced a Phase 1/2 study designed to evaluate the safety, radiation dosimetry, and preliminary diagnostic performance of [18F]FPyQCP in detecting colorectal cancer (CRC), gastric cancer (GC), pancreatic ductal adenocarcinoma (PDAC), invasive lobular breast cancer (ILC), and epithelial ovarian cancer (EOC).
* On February 24, 2026- AstraZeneca initiated a Phase I/II Open-label Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD5863, a T Cell-engaging Bispecific Antibody That Targets Claudin 18.2 (CLDN18.2) and CD3 in Adult Participants With Advanced or Metastatic Solid Tumors
* On February 23, 2026- Bristol-Myers Squibb conducted a phase 2/3 study is to assess the safety and efficacy of BMS-986504, a selective, MTA-cooperative PRMT5 inhibitor, in combination with Nab-paclitaxel/Gemcitabine (nab-p/gem) versus placebo in combination with nab-p/gem, in participants with untreated metastatic Pancreatic Ductal Adenocarcinoma (PDAC) with homozygous methylthioadenosine phosphorylase (MTAP) deletion.
* On February 23, 2026- Amplia Therapeutics Limited initiated a study is testing narmafotinib, a type of drug called a focal adhesion kinase (FAK) inhibitor, when it is given in combination with 4 chemotherapy drugs in a regimen called FOLFIRINOX, to patients who have pancreatic cancer which has metastasised (spread). The study is being run in 2 parts.
* On February 23, 2026- EXACT Therapeutics AS announced a phase 2 study is to assess the efficacy and safety of Acoustic Cluster Therapy (ACT) when given in addition to chemotherapy for treatment of Locally Advanced Pancreatic Cancer.
* DelveInsight's Pancreatic Ductal Adenocarcinoma pipeline report depicts a robust space with 80+ active players working to develop 80+ pipeline therapies for Pancreatic Ductal Adenocarcinoma treatment.
* The leading Pancreatic Ductal Adenocarcinoma Companies such as Cardiff Oncology, XOMA, Alphamab, Cantargia, RenovoRx, Syntrix Biosystems, Eucure Biopharma, Panbela Therapeutics, Jeil Pharmaceutical, Elicio Therapeutics, Cend Therapeutics, SignalChem Lifesciences, Bristol-Myers Squibb, AstraZeneca, REVOLUTION Medicines, Arcus Biosciences, ZielBio, Surface Oncology, Incyte Corporation, I-Mab Biopharma, Medicenna Therapeutics, and Tarveda Therapeutics and others.
* Promising Pancreatic Ductal Adenocarcinoma Pipeline Therapies such as Chiauranib, Albumin-paclitaxel Injection, Gemcitabine Injection, Zimberelimab, Quemliclustat, Onvansertib, Nanoliposomal irinotecan, Leucovorin and others.

Stay ahead with the most recent pipeline outlook for Pancreatic Ductal Adenocarcinoma. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Pancreatic Ductal Adenocarcinoma Treatment Drugs [https://www.delveinsight.com/sample-request/pancreatic-ductal-adenocarcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Pancreatic Ductal Adenocarcinoma Emerging Drugs Profile

* Onvansertib: Cardiff Oncology

Onvansertib, an oral highly-selective PLK1 inhibitor, which we are evaluating in combination with standard-of-care (SOC) therapeutics in clinical programs targeting indications such as KRAS-mutated metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma, and metastatic castrate-resistant prostate cancer. These programs and our broader development strategy are designed to target tumor vulnerabilities in order to overcome treatment resistance and deliver superior clinical benefit compared to the SOC.

* Nadunolimab: Cantargia

Nadunolimab is a humanised monoclonal antibody lacking fucose, being developed by Cantargia, for the treatment of solid tumours, including non-small cell lung cancer (NSCLC) and pancreatic cancer. Nadunolimab is a first-in-class anti-IL1RAP antibody, currently evaluated with standard of care chemotherapy or checkpoint inhibitor in five phase I/II clinical trials with a primary focus on PDAC and NSCLC. Nadunolimab induces ADCC and blocks signaling of both IL-1 and IL-1, counteracting thecontribution of IL-1 to the immune suppressive tumor microenvironment and development of resistance to chemotherapy

* Zimberelimab: Arcus Biosciences

Zimberelimab is a monoclonal antibody that binds pd-1 restoring the antitumor activity of T-cells. Zimberelimab was in-licensed by Arcus to enable the development of precision combination regimens with The most advanced study with zimberelimab is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer, evaluating zimberelimab in combination with domvanalimab, an anti-TIGIT monoclonal antibody, and etrumadenant, the first and only dual A2a/A2b adenosine receptor antagonist in the clinic. Zimberelimab is also being evaluated as monotherapy in a tumor agnostic, biomarker-selected Phase 1b trial for cancers with no approved anti-PD-1 treatment options. full line-of-sight to the commercialization of innovative therapies for all patients who may benefit.

The Pancreatic Ductal Adenocarcinoma Pipeline Report Provides Insights into

* The report provides detailed insights about companies that are developing therapies for the treatment of Pancreatic Ductal Adenocarcinoma with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Pancreatic Ductal Adenocarcinoma Treatment.
* Pancreatic Ductal Adenocarcinoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Pancreatic Ductal Adenocarcinoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Pancreatic Ductal Adenocarcinoma market

Explore groundbreaking therapies and clinical trials in the Pancreatic Ductal Adenocarcinoma Pipeline. Access DelveInsight's detailed report now! @ New Pancreatic Ductal Adenocarcinoma Drugs [https://www.delveinsight.com/sample-request/pancreatic-ductal-adenocarcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Pancreatic Ductal Adenocarcinoma Companies

Cardiff Oncology, XOMA, Alphamab, Cantargia, RenovoRx, Syntrix Biosystems, Eucure Biopharma, Panbela Therapeutics, Jeil Pharmaceutical, Elicio Therapeutics, Cend Therapeutics, SignalChem Lifesciences, Bristol-Myers Squibb, AstraZeneca, REVOLUTION Medicines, Arcus Biosciences, ZielBio, Surface Oncology, Incyte Corporation, I-Mab Biopharma, Medicenna Therapeutics, and Tarveda Therapeutics and others.

Pancreatic Ductal Adenocarcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

* Oral
* Intravenous
* Subcutaneous

Pancreatic Ductal Adenocarcinoma Products have been categorized under various Molecule types such as

* Small molecule
* Cell Therapy
* Peptides
* Polymer
* Small molecule
* Gene therapy

Unveil the future of Pancreatic Ductal Adenocarcinoma Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Pancreatic Ductal Adenocarcinoma Market Drivers and Barriers [https://www.delveinsight.com/sample-request/pancreatic-ductal-adenocarcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Pancreatic Ductal Adenocarcinoma Pipeline Report

* Coverage- Global
* Pancreatic Ductal Adenocarcinoma Companies- Cardiff Oncology, XOMA, Alphamab, Cantargia, RenovoRx, Syntrix Biosystems, Eucure Biopharma, Panbela Therapeutics, Jeil Pharmaceutical, Elicio Therapeutics, Cend Therapeutics, SignalChem Lifesciences, Bristol-Myers Squibb, AstraZeneca, REVOLUTION Medicines, Arcus Biosciences, ZielBio, Surface Oncology, Incyte Corporation, I-Mab Biopharma, Medicenna Therapeutics, and Tarveda Therapeutics and others.
* Pancreatic Ductal Adenocarcinoma Pipeline Therapies- Chiauranib, Albumin-paclitaxel Injection, Gemcitabine Injection, Zimberelimab, Quemliclustat, Onvansertib, Nanoliposomal irinotecan, Leucovorin and others.
* Pancreatic Ductal Adenocarcinoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Pancreatic Ductal Adenocarcinoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Pancreatic Ductal Adenocarcinoma Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Pancreatic Ductal Adenocarcinoma Companies, Key Products and Unmet Needs [https://www.delveinsight.com/sample-request/pancreatic-ductal-adenocarcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Contents

* Introduction
* Executive Summary
* Pancreatic Ductal Adenocarcinoma: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Pancreatic Ductal Adenocarcinoma- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* NIS 793: XOMA
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* CEND 1: Cend Therapeutics
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I/II)
* DCC-3116: Deciphera Pharmaceuticals
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* RMC-6236: REVOLUTION Medicines
* Drug profiles in the detailed report.....
* Inactive Products
* Pancreatic Ductal Adenocarcinoma Key Companies
* Pancreatic Ductal Adenocarcinoma Key Products
* Pancreatic Ductal Adenocarcinoma- Unmet Needs
* Pancreatic Ductal Adenocarcinoma- Market Drivers and Barriers
* Pancreatic Ductal Adenocarcinoma- Future Perspectives and Conclusion
* Pancreatic Ductal Adenocarcinoma Analyst Views
* Pancreatic Ductal Adenocarcinoma Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=pancreatic-ductal-adenocarcinoma-treatment-pipeline-shows-strong-momentum-as-80-pharma-companies-in-the-race-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/pancreatic-ductal-adenocarcinoma-pipeline-insight

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.